Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro (Q33984351)
scientific article
Language:
(P31) (Q13442814)
(P304) 12447-12454
(P407) (Q1860)
(P433) 19
(P478) 79
(P577) Saturday, October 1, 2005
(P1433) (Q1251128)
(P1476) "Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro" (language: en)
(P2093) M Mink
S M Mosier
S Janumpalli
D Davison
L Jin
T Melby
P Sista
J Erickson
D Lambert
S A Stanfield-Oakley
M Salgo
N Cammack
T Matthews
M L Greenberg
(P2860) (Q42844743)
(Q37742855)
(Q35972076)
(Q37596642)
(Q24563937)
(Q42626443)
(Q37415987)
(Q35978823)
(Q34184881)
(Q28183380)
(Q34415921)
(Q29619254)
(Q28362194)
(Q28346124)
(Q33813025)
(Q39612212)
(Q29620710)
(Q28646880)
(Q28379310)
(Q41071776)
(Q27738021)
(Q28646867)
(Q28369033)
(Q28646828)
(Q29547734)
(Q29615351)
(Q45021999)
(Q48003659)
(Q44195752)
(Q44457921)
(Q44094005)
(Q45741672)
other details
description scientific article

External Links